Market Access & Reimbursement

Securing early access and reimbursement for your products

Veristat Market Access team members provide strategic advice on national early access programs, write HTA/reimbursement dossiers for submission to national HTA bodies and prepare documentation for liaison with private healthcare insurance.

Furthermore, our team supports clients with joint EMA/HTA scientific advice meetings to optimize development plans for successful regulatory and reimbursement approvals.

It's never to early to start.   Let's Talk. 

Reimbursement Solutions Across the Clinical Development and Commercialization Lifecycle

Market Access Roadmap

  • - P&R Strategy
  • - Routes to Market Access
  • - Early Access Reimbursement
  • - Value-based contract solution
drug and biologic market access roadmap

Health Technology Assessment (HTA)

  • - Dossier strategy
  • - Value dossier
  • - National HTA dossiers
  • - Price review
health technology assessment for market access and reimbursement


  • - Competitor Analysis
  • - Pricing Analyses & Strategy
  • - Negotiation
  • - Price Optimization tactics

Payor Authority Management

  • - Payor and HCP Research
  • - Objection Handling
  • - Advisory Boards
  • - KOL liaison

Ready to develop your reimbursement strategy?


Learn More with These Resources

Fact Sheet

Rare Disease Fact Sheet


Regulatory Guidance Monthly Review - February 2024


Regulatory Guidance Monthly Review - January 2024